Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aeglea Biothera (AGLE)

Aeglea Biothera (AGLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aeglea Biothera 221 CRESCENT STREET BUILDING 23 SUITE 105 WALTHAM MA 02453 USA

www.aegleabio.com P: 617-651-5940

Description:

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas.

Key Statistics

Overview:

Market Capitalization, $K 48,627
Enterprise Value, $K 13,767
Shares Outstanding, K 4,049
Annual Sales, $ 2,330 K
Annual Net Income, $ -83,810 K
Last Quarter Sales, $ 690 K
Last Quarter Net Income, $ -217,080 K
EBIT, $ -215,980 K
EBITDA, $ -214,740 K
60-Month Beta 2.57
% of Insider Shareholders 6.60%
Float, K 3,782
% Float 93.40%
Short Volume Ratio 0.79

Growth:

1-Year Return -61.26%
3-Year Return -94.14%
5-Year Return -93.90%
5-Year Revenue Growth -55.28%
5-Year Earnings Growth 45.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.43 on 11/09/23
Next Earnings Date N/A
Earnings Per Share ttm -55.75
EPS Growth vs. Prev Qtr 91.73%
EPS Growth vs. Prev Year 27.79%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 09/08/23

AGLE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -146.87%
Profit Margin % -3,597.00%
Debt/Equity 0.00
Price/Sales 19.19
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -64.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar